stoxline Quote Chart Rank Option Currency Glossary
Anavex Life Sciences Corp. (AVXL)
5.28  0.14 (2.72%)    03-01 16:00
Open: 5.19
High: 5.41
Volume: 989,244
Pre. Close: 5.14
Low: 5.13
Market Cap: 427(M)
Technical analysis
2024-03-01 4:50:56 PM
Short term     
Mid term     
Targets 6-month :  7.11 1-year :  8.05
Resists First :  6.09 Second :  6.89
Pivot price 5.41
Supports First :  4.79 Second :  3.98
MAs MA(5) :  5.2 MA(20) :  5.46
MA(100) :  6.49 MA(250) :  7.58
MACD MACD :  -0.4 Signal :  -0.4
%K %D K(14,3) :  32.8 D(3) :  32.3
RSI RSI(14): 42.9
52-week High :  10.44 Low :  4.79
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ AVXL ] has closed above bottom band by 40.5%. Bollinger Bands are 32.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 5.41 - 5.44 5.44 - 5.47
Low: 5.07 - 5.1 5.1 - 5.12
Close: 5.24 - 5.28 5.28 - 5.32
Company Description

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Headline News

Sat, 02 Mar 2024
Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Sold by Citigroup Inc. - AmericanBankingNEWS

Thu, 29 Feb 2024
Swiss National Bank Buys 4400 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) - AmericanBankingNEWS

Tue, 27 Feb 2024
SHAREHOLDER ALERT: Potential Recovery for Anavex Life Sciences Corp. (AVXL) Investors - - TipRanks

Mon, 26 Feb 2024
Anavex Life Sciences Invited to Present at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference - The Globe and Mail

Thu, 08 Feb 2024
Anavex Life Sciences Corp. (NASDAQ:AVXL) Q1 2024 Earnings Call Transcript - Yahoo Finance

Wed, 07 Feb 2024
Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update - Barron's

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 82 (M)
Shares Float 80 (M)
Held by Insiders 3.1 (%)
Held by Institutions 32 (%)
Shares Short 20,130 (K)
Shares Short P.Month 20,070 (K)
Stock Financials
EPS -0.55
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.64
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -20.8 %
Return on Equity (ttm) -31.9 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -29 (M)
Levered Free Cash Flow -18 (M)
Stock Valuations
PE Ratio -9.78
PEG Ratio 0
Price to Book value 3.2
Price to Sales 0
Price to Cash Flow -14.8
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android